Mucormycosis (Rhino-orbital-cerebral)

Rhino-orbital-cerebral mucormycosis is a rapidly progressive, angioinvasive fungal infection and a medical/surgical emergency with mortality rates of 50–80%, rising to >90% with disseminated or cerebral involvement. [1-2] Early recognition and immediate multidisciplinary intervention are the most critical determinants of survival. [3]

The following figure from a 2026 NEJM review illustrates the clinical and diagnostic spectrum of mucormycosis, including periorbital cellulitis, necrotic eschars, palatal necrosis, sinus CT findings, and the characteristic broad, ribbon-like, pauci-septate hyphae on histopathology:

• Key HPI questions: Onset and progression of facial pain, nasal congestion/discharge, headache, visual changes (diplopia, blurred vision, vision loss), facial numbness, tooth pain
• Symptom characterization: Unilateral facial pain/swelling → periorbital edema → visual changes; progression over hours to days [1][4]
• Timing: Rapid progression is the hallmark — symptoms can evolve from mild sinusitis to orbital/cerebral involvement within 24–72 hours [1]
• Triggers: Recent DKA episode, recent high-dose corticosteroid use, recent chemotherapy, recent COVID-19 illness [1]
• Associated symptoms: Fever, bloody/dark nasal discharge, anosmia, odontogenic pain, seizures, altered mental status [1][5]
• Important negatives: Absence of trauma (rules out cutaneous form), absence of cough/hemoptysis (rules out pulmonary form)

• Black necrotic eschar on nasal mucosa, turbinates, or palate — pathognomonic for angioinvasive fungal infection [1][3]
• Periorbital cellulitis, proptosis, ophthalmoplegia — indicates orbital extension [1][6]
• Vision loss (especially no light perception) — associated with higher mortality [2]
• Cranial nerve palsies (CN III, IV, V1, V2, VI) — suggests cavernous sinus involvement [1]
• Impaired V2 nerve function — independently associated with higher mortality [2]
• Altered mental status, seizures, focal neurologic deficits — indicates cerebral extension, a surgical emergency [1][4]
• Rapid clinical deterioration despite antibiotics in an immunocompromised or diabetic patient [3]

• Relevant contributors:
  • Prolonged high-dose glucocorticoids — major risk factor [1]
  • Voriconazole prophylaxis — NOT active against Mucorales and may select for breakthrough mucormycosis [1]
  • Ibrutinib, CAR-T therapy — recently identified risk factors [1]
  • Deferoxamine (iron chelator) — increases iron availability to Mucorales; contraindicated [7]
• First-line treatment: Liposomal amphotericin B 5–10 mg/kg/day IV (10 mg/kg/day if CNS involvement) [3]
• Alternatives/step-down: Isavuconazole (FDA-approved for mucormycosis) or posaconazole delayed-release tablets — for renal failure, intolerance, or step-down maintenance [3][8-9]
• Contraindicated antifungals: Echinocandins, fluconazole, itraconazole, voriconazole — NO activity against Mucorales [1]
• Key caution: Monitor renal function closely on amphotericin B; hypokalemia is the most common adverse effect (50–70%) [5][10]

• Acute phase: NPO if surgical debridement planned; otherwise standard nutrition support
• DKA management: Aggressive IV fluid resuscitation, insulin infusion, electrolyte correction — metabolic correction is a pillar of treatment [1]
• Long-term: Strict glycemic control (HbA1c <8%) — elevated HbA1c is a significant mortality predictor [11]
• Iron supplementation: Avoid unnecessary iron supplementation, as iron overload states promote Mucorales growth [1][7]

• HEENT: Nasal congestion, bloody/purulent discharge, facial pain/swelling, tooth pain, vision changes, eye pain, tearing
• Neurologic: Headache, facial numbness (V2 distribution), diplopia, seizures, altered mental status, focal weakness
• Pulmonary: Cough, dyspnea, hemoptysis, pleuritic chest pain (screen for sinopulmonary extension) [1]
• Constitutional: Fever, malaise, weight loss
• GI: Nausea, vomiting (may indicate DKA or GI mucormycosis)
• Skin: Any necrotic wounds or eschars at other sites (disseminated disease) [1]

• Collateral: Confirm diabetes control history, recent steroid use (dose and duration), recent hospitalization, COVID-19 history, chemotherapy regimen, transplant status and immunosuppression regimen
• Family history: Diabetes mellitus (type 1 or 2), hematologic malignancies
• Social context: IV drug use (risk for disseminated/endocarditis-associated mucormycosis), occupational exposure to soil/construction (environmental Mucorales exposure) [1]

• Diabetes mellitus (especially with DKA) — the predominant risk factor for ROCM [1][12]
• Hematologic malignancies and prolonged neutropenia [1][3]
• Hematopoietic cell transplantation (median onset ~135 days post-HCT) [6]
• Solid organ transplantation [1]
• Prolonged high-dose glucocorticoid use [1]
• COVID-19 (particularly with concurrent DM and steroid use) [1][13]
• Iron overload states and deferoxamine therapy [1]
• Severe aplastic anemia [1]
• HbA1c >8%, age >60 years — independent mortality predictors [11]

• Invasive aspergillosis — most important mimic; septate, dichotomously branching hyphae (vs. broad, pauci-septate in Mucorales); galactomannan-positive [1][14]
• Bacterial orbital cellulitis — typically responds to antibiotics; lacks necrotic eschars
• Orbital apex syndrome from other causes (tumor, granulomatosis with polyangiitis, sarcoidosis)
• Cavernous sinus thrombosis — may coexist with ROCM; similar cranial nerve findings
• Invasive fusariosis or scedosporiosis — other angioinvasive molds; require culture/histopath for differentiation [1]
• Squamous cell carcinoma of the sinuses — can mimic destructive sinus disease
• Granulomatosis with polyangiitis (GPA) — midline destructive lesion, ANCA-positive
• Distinguishing pearl: Negative galactomannan and β-D-glucan in the setting of angioinvasive mold infection strongly favors mucormycosis over aspergillosis [6][15]

• Critical to elicit: Diabetes (type, duration, control, DKA history), hematologic malignancy, transplant history, HIV/AIDS, chronic steroid use
• Previous episodes: Recurrence is possible, especially if underlying immunosuppression persists
• Surgical history: Prior sinus surgery, orbital surgery, dental procedures
• Chronic illnesses: Chronic kidney disease (affects amphotericin B dosing), liver disease, iron overload conditions

• Vital signs: Fever (present in ~70% of cases), tachycardia; check for Kussmaul respirations (DKA) [5]
• Nasal exam: Black necrotic eschar on turbinates or septum, purulent/bloody discharge, septal ulceration [1][5]
• Oral exam: Palatal ischemia or necrosis (especially with maxillary sinus involvement), molar/premolar tenderness [1]
• Orbital exam: Periorbital edema/erythema, proptosis, chemosis, ophthalmoplegia, ptosis, decreased visual acuity, afferent pupillary defect [2][5]
• Cranial nerves: Test CN II–VI carefully — deficits suggest cavernous sinus invasion [1][6]
• Neurologic: Mental status, focal deficits, signs of meningismus
• Skin: Inspect for necrotic eschars elsewhere (disseminated disease)
• Key finding: Necrotic lesions in oral cavity/sinuses found in 87% of cases in one series [5]

• Recommended labs:
  • BMP (glucose, creatinine, potassium — baseline for amphotericin B monitoring)
  • CBC with differential (assess for neutropenia)
  • HbA1c
  • ABG/VBG (assess for metabolic acidosis/DKA)
  • Blood glucose, serum ketones
  • LFTs, coagulation studies
  • Serum iron studies (iron overload assessment)
• Expected abnormalities: Hyperglycemia, metabolic acidosis, elevated anion gap (DKA), hypokalemia (from amphotericin B) [5]
• Rule-out labs: Serum galactomannan and β-D-glucan are negative in mucormycosis (Mucorales lack these cell wall components) — a negative result in the setting of suspected invasive mold infection should raise suspicion for mucormycosis [6][15]
• Emerging diagnostics: Serum Mucorales qPCR (75–80% sensitivity; positive in 91% of hematogenous cases) — increasingly available commercially (MucorGenius, MycoGENIE) [6][16]
• Monitoring: Renal function and potassium at least every other day during amphotericin B therapy [10][15]

• First-line: CT of paranasal sinuses (with contrast) — assess for mucosal thickening, bony erosion, peri-antral fat infiltration, orbital extension [3][17]
• Gold standard for orbital/cerebral involvement: MRI with gadolinium — substantially greater sensitivity than CT for detecting orbital soft tissue invasion, cavernous sinus involvement, meningeal enhancement, perineural spread, and cerebral extension [3][18]
• Important findings:
  • Sinus opacification with bony erosion
  • Orbital fat stranding, extraocular muscle thickening
  • Cavernous sinus enhancement/thrombosis
  • Meningeal enhancement (cerebral extension)
  • Frontal lobe infarction (from internal carotid artery invasion) [1][18]
• Critical caveat: CT and MRI may be unremarkable in early disease — a normal scan does NOT rule out mucormycosis; repeat imaging and endoscopy are essential [1]
• Staging: Once ROCM is confirmed, obtain chest CT to evaluate for pulmonary involvement [1]
• Follow-up: Weekly CT/MRI recommended in unstable patients [3]

• Nasal endoscopy with biopsy — the most critical diagnostic procedure; brush biopsy of ulcerations and necrotic eschars [1][3]
• Histopathology: PAS and GMS stains showing broad (7–15 μm), ribbon-like, pauci-septate hyphae with non-dichotomous (right-angle) branching — pathognomonic [1]
• Direct microscopy: KOH wet mount or calcofluor/Blankophor fluorescence staining for rapid identification [1]
• Culture: Sabouraud's glucose agar at 25–37°C; grows rapidly but culture is positive in only ~50% of cases [1][16]
• MALDI-TOF MS: Rapid species identification from culture isolates [1]
• Molecular: Mucorales-specific PCR (serum, BAL, tissue) — emerging as a key early diagnostic tool [1][6][16]
• Metagenomic cell-free DNA sequencing: Promising but not yet validated for routine use [1]

• Indications: Baseline ECG before initiating amphotericin B (monitor for electrolyte-related arrhythmias, especially hypokalemia-induced QT prolongation)
• If isavuconazole is used: Note that isavuconazole can shorten the QTc interval — contraindicated in patients with familial short QT syndrome [3]
• Monitor for: Hypokalemia-related changes (U waves, ST depression, T wave flattening) during amphotericin B therapy

• Clinical summary: ROCM is a medical and surgical emergency requiring immediate multidisciplinary intervention. The five pillars of management are: (1) early detection, (2) prompt antifungal therapy, (3) surgical debridement, (4) reversal of immunodeficiency, and (5) correction of metabolic abnormalities. [1]
• Severity stratification:
  • Isolated sinonasal: survival ~82% [19]
  • Rhino-orbital: intermediate prognosis
  • Rhino-orbito-cerebral: survival 27% (lowest) [19]
  • Intracranial extension: mortality 71% [19]
• Typical presentation: Diabetic patient in DKA with unilateral facial pain/swelling, bloody nasal discharge, periorbital edema progressing to proptosis and vision loss [4][12]
• Atypical presentations: May present as isolated headache, dental pain, or fever of unknown origin in neutropenic patients [1]
• Complications: Cavernous sinus thrombosis, internal carotid artery invasion with stroke, frontal lobe abscess, orbital exenteration, disseminated disease [1][18]

Initial stabilization

• ABCs, IV access, continuous monitoring
• Correct DKA aggressively: IV fluids, insulin drip, electrolyte repletion [1]
• Rapidly reduce glucocorticoid dose to the lowest effective dose [1]

Antifungal therapy (start empirically if high suspicion — do not wait for culture):

• Liposomal amphotericin B 5 mg/kg/day IV (standard dose) [3]
• Escalate to 10 mg/kg/day if CNS involvement (based on animal models and clinical data) [3][15]
• Alternative if renal failure/intolerance: Isavuconazole (loading: 200 mg IV/PO q8h × 6 doses, then 200 mg daily) or posaconazole delayed-release tablets (300 mg BID day 1, then 300 mg daily) [3][9]
• Duration: Continue until imaging resolution and immune reconstitution; no fixed duration — typically 4–6 weeks minimum of primary therapy, often longer [3][15]

Surgical intervention

• Urgent ENT/surgical consultation for debridement — perform as soon as feasible, in parallel with antifungal therapy [3][19]
• Endoscopic sinus debridement with removal of all necrotic tissue
• Second-look surgery at day 7 recommended to reassess margins [20]
• Orbital exenteration if globe is non-viable (NLP vision) with extensive orbital involvement — all exenteration patients survived in one 3-year cohort [2]
• Combined surgical + medical therapy reduces mortality from 88% to 32% compared to antifungals alone [19]

Adjunctive measures

• G-CSF or GM-CSF if neutropenic [1]
• Granulocyte transfusions in selected cases pending neutrophil recovery [1]
• Hyperbaric oxygen — may be beneficial in selected diabetic patients with sino-orbital/rhinocerebral disease [1]
• Deferasirox is NOT recommended (randomized pilot trial showed no benefit) [21]

Step-down/maintenance therapy

• [3][22]

• All suspected ROCM patients require immediate hospital admission, typically to an ICU or step-down unit [3]
• Admission criteria: Any patient with suspected invasive fungal sinusitis in the setting of immunosuppression or uncontrolled diabetes
• ICU indications: DKA, hemodynamic instability, altered mental status, cerebral involvement, post-operative monitoring after extensive debridement
• Specialist consultation triggers (all urgent):
  • Infectious disease — antifungal management
  • ENT/otolaryngology — endoscopic evaluation and surgical debridement
  • Ophthalmology — orbital assessment, visual acuity monitoring
  • Neurosurgery — if intracranial extension
  • Endocrinology — DKA/glycemic management
• Discharge criteria: Clinical stability, resolving imaging, transition to oral step-down antifungal therapy, controlled underlying condition, reliable outpatient follow-up established
• ROCM is never an outpatient diagnosis — there is no role for observation or discharge from the ED [4]

• Follow-up timing: Weekly imaging (CT or MRI) during active treatment; ENT endoscopic reassessment at 1–2 week intervals initially [3]
• Duration of antifungal therapy: Continue until complete resolution on imaging AND immune reconstitution — often months [3]
• Long-term monitoring: Renal function, electrolytes, hepatic function during prolonged antifungal therapy; ophthalmologic follow-up for visual outcomes
• Symptoms requiring immediate reassessment:
  • New or worsening facial pain, swelling, or numbness
  • Any visual changes (blurring, diplopia, vision loss)
  • New headache, confusion, seizures, or focal neurologic deficits
  • Fever recurrence
• Patient counseling:
  • This is a life-threatening infection requiring prolonged treatment
  • Strict glycemic control is essential to prevent recurrence
  • Functional and cosmetic sequelae (vision loss, facial disfigurement) may be permanent
  • Recovery is slow — imaging improvement in mucormycosis takes longer than in other fungal infections [15]
• Expected recovery: Partial or complete response typically achieved by 4–6 weeks of primary therapy, but total treatment duration is often months; recurrence is possible if immunosuppression persists [3][15]

1. Mucormycosis. — Kontoyiannis DP, Walsh TJ. The New England Journal of Medicine. 2026.

2. Survival and Prognostic Factors in Rhino-Orbito-Cerebral Mucormycosis: A 3-Year Cohort Study. — Zia Z, Sajadi MJ, Bazrafshan H, Khademi B, Janipour M. Scientific Reports. 2025.

3. Global Guideline for the Diagnosis and Management of Mucormycosis: An Initiative of the European Confederation of Medical Mycology in Cooperation With the Mycoses Study Group Education and Research Consortium. — Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. The Lancet. Infectious Diseases. 2019.

4. Rhino-Orbital Cerebral Mucormycosis in a Diabetic Patient: An Emergency Medicine Case Report. — Sweet R, Hovenden M, Harvey CE, Peterson W, Lott I. The Journal of Emergency Medicine. 2023.

5. Retrospective Evaluation of Mucormycosis Cases at a Tertiary Care Center Between 2000 and 2020 in Türkiye. — Öztürk Belik H, Heper Y, Kazak E, et al. Mycopathologia. 2026.

6. American Society of Transplantation and Cellular Therapy Series: #8-Management and Prevention of Non-Aspergillus Molds in Hematopoietic Cell Transplantation Recipients. — Douglas AP, Lamoth F, John TM, et al. Transplantation and Cellular Therapy. 2025.

7. Mucormycosis in 2023: An Update on Pathogenesis and Management. — Alqarihi A, Kontoyiannis DP, Ibrahim AS. Frontiers in Cellular and Infection Microbiology. 2023.

8. FDA Orange Book. — FDA Orange Book. 2026.

9. Part 2: Mucormycosis: Focus on Therapy. — Lynch JP, Zhanel GG. Expert Review of Anti-Infective Therapy. 2023.

10. Prevention and Treatment of Cancer-Related Infections. — Updated 2026-03-11. National Comprehensive Cancer Network.

11. Analysis of COVID-19-associated Rhino-Orbital-Cerebral Mucormycosis Patients in a Tertiary Care Center in Northern India. — Yadav H, Sen S, Nath T, et al. Indian Journal of Ophthalmology. 2022.

12. Mucormycosis. — Czech MM, Cuellar-Rodriguez J. Infectious Disease Clinics of North America. 2025.

13. COVID-19 Associated Mucormycosis in Assiut University Hospitals: A Multidisciplinary Dilemma. — Farghly Youssif S, Abdelrady MM, Thabet AA, et al. Scientific Reports. 2022.

14. CT Findings for Differentiating Pulmonary Mucormycosis From Invasive Pulmonary Aspergillosis, Prior to Invasive Procedure Such as a Biopsy or Surgery: A 22-Year Single-Center Experience. — Jang HM, Kim MY, Lim SY, et al. Mycoses. 2025.

15. Definition, Diagnosis, and Management of COVID-19-associated Pulmonary Mucormycosis: Delphi Consensus Statement From the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India. — Muthu V, Agarwal R, Patel A, et al. The Lancet. Infectious Diseases. 2022.

16. The Diagnosis of Mucormycosis by PCR in Patients at Risk: A Systematic Review and Meta-Analysis. — Brown L, Tschiderer L, Alanio A, et al. EClinicalMedicine. 2025.

17. Lung and Sinus Fungal Infection Imaging in Immunocompromised Patients. — Lamoth F, Prakash K, Beigelman-Aubry C, Baddley JW. Clinical Microbiology and Infection : The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases. 2024.

18. Multicenter Analysis of General Presentations and Imaging Features in Cerebral MUCORmycosis (MAGICMUCOR): Towards Different Entities. — de La Porte C, Provost C, Coste A, et al. Medical Mycology. 2025.

19. Impact of Anatomical Extent and Combined Surgical-Medical Therapy on Survival in Sinonasal and Rhino-Orbito-Cerebral Mucormycosis: A 14-Year Retrospective ENT Cohort. — Kozan G, Dedeoğlu S, Ayral M, Akdağ M. Journal of Clinical Medicine. 2025.

20. Systematic Surgical Reassessment Combined With Liposomal Amphotericin B: The MICA Protocol. — Gervais M, Aubertin M, Verillaud B, et al. Acta Oto-Laryngologica. 2026.

21. Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for Diagnosis, Prevention, and Treatment of Invasive Fungal Diseases in Paediatric Patients With Cancer or Allogeneic Haemopoietic Stem-Cell Transplantation. — Groll AH, Castagnola E, Cesaro S, et al. The Lancet. Oncology. 2014.

22. Rhino-Orbito-Cerebral Mucormycosis in New-Onset Type 1 Diabetes Mellitus: A Case-Based Short Review. — Sharifi I, Razzeto A, Sacco SB, et al. The American Journal of the Medical Sciences. 2026.